Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$93.81−5.56 (-5.60%)
Close on Nov 17, 2026Market cap $8.27BP/E –Yield –
Spyre Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Spyre Therapeutics's enterprise value was $8.31B on Nov 11, 2026, against $1.33B a year earlier. Over the last 5 years it ranged from -$197.64M to $8.31B, with a median of $376.16M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $8.31B | +455.7% |
| 2025 | Dec 31, 2025 | $1.49B | +91.1% |
| 2024 | Dec 31, 2024 | $782.26M | – |
| 2023 | Dec 29, 2023 | -$116.47M | – |
| 2022 | Dec 30, 2022 | -$47.53M | -139.0% |
| 2021 | Dec 31, 2021 | $121.78M | -42.5% |
| 2020 | Dec 31, 2020 | $211.75M | +60.1% |
| 2019 | Dec 31, 2019 | $132.27M | +31.2% |
| 2018 | Dec 31, 2018 | $100.82M | +201.7% |
| 2017 | Dec 29, 2017 | $33.42M | – |
| 2016 | Dec 30, 2016 | -$9.58M | – |
See a number that looks wrong?